Researchers at the University of Edinburgh advanced a new cell-therapy strategy aimed at treating advanced liver disease, targeting patients facing dire outcomes from cirrhosis and liver failure. The approach uses the patient’s own immune cells to help repair damaged liver tissue, with early clinical findings described as a potential paradigm shift. The report frames the therapy as leveraging immune cells to promote regeneration and improve disease trajectory, though specific trial design, endpoints, and enrollment numbers were not detailed in the provided excerpt. Still, the work adds to the accelerating pipeline of autologous cell therapies moving into harder-to-treat organ indications. For biotech stakeholders, the Edinburgh development stands out as a cross-current with broader liver-directed immunotherapies and cellular modalities seeking durable benefit without transplant dependence.